Your browser doesn't support javascript.
loading
Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.
Sebio, Ana; Constantinidou, Anastasia; Benson, Charlotte; Antoniou, Georgios; Messiou, Christina; Miah, Aisha; Zaidi, Shane; Petruckevitch, Ann; Al-Muderis, Omar; Thway, Khin; VAN DER Graaf, Winette T; Jones, Robin L.
Afiliación
  • Sebio A; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Constantinidou A; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Benson C; Medical School, University of Cyprus, Nicosia, Cyprus.
  • Antoniou G; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Messiou C; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Miah A; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Zaidi S; Institute of Cancer Research, London, U.K.
  • Petruckevitch A; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Al-Muderis O; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Thway K; Statistics Department, Royal Marsden Hospital, London, U.K.
  • VAN DER Graaf WT; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
  • Jones RL; Sarcoma Unit, Royal Marsden Hospital, London, U.K.
Anticancer Res ; 39(1): 347-351, 2019 Jan.
Article en En | MEDLINE | ID: mdl-30591479
BACKGROUND/AIM: Treatment options for patients with metastatic soft tissue sarcomas are limited. Re-challenge with a previously successful gemcitabine-based regimen is common. There are no published data to support this practice. PATIENTS AND METHODS: We conducted a retrospective search to identify patients re-challenged with gemcitabine-based chemotherapy (GBC) from 2003 to 2015. RESULTS: Twenty-nine patients re-challenged with gemcitabine were identified. The response rate for initial GBC was 55% (n=15) and for re-challenge GBC 26% (n=6). The median progression-free survival was 11.1 months (95%CI=7.2-11.9) for initial GBC and 5.3 months (95%CI=2.0-7.5) for re-challenge GBC. Overall survival following gemcitabine re-challenge was 12.2 months (95%CI=7.0-18.2). Twelve out of 26 evaluable patients (46%) treated with re-challenge GBC experienced grade 3-4 adverse events (CTCAE 4.03) with 31% (n=8) of patients requiring dose reduction. CONCLUSION: In selected patients, gemcitabine re-challenge can be considered in advanced sarcomas, however, this approach is associated with toxicity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Desoxicitidina Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article Pais de publicación: Grecia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Desoxicitidina Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Anticancer Res Año: 2019 Tipo del documento: Article Pais de publicación: Grecia